A survey was done in which thousands of advanced cancers indicated a way to detect those that respond to revolutionary therapies that unleash an immune response against tumours. However, the results show difficulty level to translate an approach into a reliable clinical test. The findings are the latest evidence to indicate that tumours having a large number of DNA mutations are more likely to respond to immunotherapies than are cancers with fewer mutation and result in longer survival for people who receive treatment.
Finding
a threshold
But the immune system is intricate, and it has proved difficult to decide what makes one tumour vulnerable to treatment but a...
